ÂÜÀòÂÒÂ×

Mike Bond brings over 25+ years of biotechnology R&D experience in analytical method development/validation, protein characterization, and CMC activities. At Janssen/Johnson & Johnson, Mike served as both Director of Analytics and Director of Large Molecule Pharma Development and Manufacturing. Under his leadership, he successfully led the commercialization from Phase I of multiple products, including monoclonal antibody therapeutics Stelara and Simponi. He brings decades of experience in multiple BLA/NDA filings as well. Mike Bond received his Ph.D. in Biochemistry from Florida State University and completed his Postdoctoral Research at Harvard Medical School.